|
Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome Clinical research trials and Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome. Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome  Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome
Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome
For Condition: Lambert-Eaton Myasthenic Syndrome
Status: Completed
Sponsor(s): FDA Office of Orphan Products Development , Duke University
Synopsis: OBJECTIVES: I. Evaluate the safety and effectiveness of 3,4-diaminopyridine (DAP) in the treatment of patients with Lambert-Eaton myasthenic syndrome (LEMS). II. Determine the side-effects and benefits associated with DAP.
Details: PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled study. Patients are randomized to receive 3,4-diaminopyridine (DAP) or placebo orally 3 times daily for 5 days, after which treatment is discontinued and patients are observed for at least 24 hours. At the end of the blinded study, patients may then elect to take open label DAP orally 3 times daily for 6 months; those who do so are monitored for clinical effects and side effects for at least 6 months.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Lambert-Eaton myasthenic syndrome (LEMS) based on weakness that predominates in proximal limb muscles and electromyography (EMG) findings of small amplitude muscle responses to nerve stimulation, which decrease further during nerve stimulation at 5 Hz and which increase at least 2-fold after maximum voluntary contraction of the muscle for 10-20 seconds Quantified Myasthenia Gravis (QMG) clinical score at least 5 --Prior/Concurrent Therapy-- Chemotherapy: No concurrent chemotherapy Endocrine therapy: Patients receiving immunosuppressants must be on the same dose of medication for at least 3 months prior to study entry Radiotherapy: No concurrent radiotherapy Surgery: No concurrent surgery Other: Patients receiving cholinesterase inhibitors must discontinue the medication at study entry if possible, or else be on the same dose of medication for at least 1 month prior to study entry --Patient Characteristics-- Hematopoietic: No significant hematologic disease Hepatic: No significant hepatic disease Renal: No significant renal disease Cardiovascular: No cardiac arrhythmia or significant cardiac disease Neurologic: No seizure disorder Other: Not pregnant Negative pregnancy test required of fertile women Effective contraception required of fertile women
Total Enrollment: 26
Location and Contact Information:
Overall Study Official:
DonaldSanders, Study Chair, Duke University
Additional Information:
Study ID Numbers: 199/13441; DUMC-577,DUMC-FDR001068
Study Start Date: August 1994
Record last reviewed: July 1998
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004832
Other Lambert-Eaton Myasthenic Syndrome Studies:
1. Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome
Related Studies:
Other Lambert-Eaton Myasthenic Syndrome Clinical Trials
Other Clinical Trials
Other Clinical Trials
Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome
|
|
|
|
|
|
|
|
